Achieve Life Sciences, Inc 10-Q for FY2026 Q3
Achieve Life Sciences, Inc. (QUIT)
10-Q
2026-11-10
For: 2026-09-30
View Original
Added on
November 10, 2026
About this 10-Q
Achieve Life Sciences, Inc filed this 10-Q on November 10, 2026, covering the quarter ended September 30, 2026 (FY2026 Q3).
Achieve Life Sciences received an FDA Complete Response Letter for cytisinicline citing manufacturing and labeling issues. It plans to resubmit in the fourth quarter of 2026 and anticipates potential approval by the end of the second quarter of 2027. AI summary
Headline figures
Quarter ended September 30, 2026, as reported in this filing, compared with the same period a year earlier where the filing states it.
- Net loss
- $12.11M
- compared with a net loss of $14.44M a year earlier
- Diluted EPS
- -$0.11
- compared with -$0.28 a year earlier